Company Overview of Opsona Therapeutics Limited
Opsona Therapeutics Limited operates as a clinical stage biopharmaceutical company. The company primarily focuses on developing drugs for the treatment of autoimmune/inflammatory diseases and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease, and atherosclerosis. Its portfolio includes OPN-305, a monoclonal/humanized antibody that reduces pro-inflammatory cytokine production associated with heart and kidney diseases, as well as capable of dampening down the body’s immune response to a donated kidney. The company’s development portfolio includes IL-1ß inhibitors. Opsona Therapeutics Limited was founded in 2004 and is based in Dublin, Ireland.
Founded in 2004
Key Executives for Opsona Therapeutics Limited
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Scientific Advisor
Co-Founder, Chief Scientific Officer and Director
Compensation as of Fiscal Year 2014.
Opsona Therapeutics Limited Key Developments
Opsona Therapeutics Limited Presents at BioEquity Europe 2015, May-20-2015 11:20 AM
May 8 15
Opsona Therapeutics Limited Presents at BioEquity Europe 2015, May-20-2015 11:20 AM. Venue: InterContinental Vienna, Vienna, Austria.
Opsona Therapeutics Limited Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM
Mar 12 15
Opsona Therapeutics Limited Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.
Opsona Therapeutics Ltd. Commences Part B of Phase II Study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor Renal Transplant Recipients At High Risk of Early Graft Dysfunction
Mar 2 15
Opsona Therapeutics Ltd. announced the continuation of its double-blind renal transplant study by the initiation of Part B of its adaptive phase II clinical trial in Extended Criteria Donors (ECD) renal transplant recipients at high risk of early graft dysfunction with its lead drug candidate OPN-305. Based on the completion of Part A of this double blind study, OPN-305 was well tolerated and deemed to be safe by the data and safety monitoring board across all dose groups with no evidence of increased risk of infection in these highly immuno-suppressed patients. The company is proceeding with Part B in a modified patient population evaluating ECD-only recipients. ECD kidneys make up the large pool of the cadaveric donor population. Currently up to 45% of ECD kidneys are discarded resulting in a significant deficit in supply versus demand. OPN-305 has the opportunity to turn borderline non-transplantable organs into viable kidneys and functioning grafts resulting in fewer ECD discards, driving an overall increase in the number of deceased donor transplants.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries